

Figure S1. The dynamic distribution of Z_{HPV16 E7} affitoxin384 in normal nude mice. (A)

The fluorescence imaging was performed using an NIR imaging system at various

time points post-injection of DyLight 755-labeled Z_{HPV16 E7} affitoxin384. (B) The

tumor/muscle fluorescence ratios at various time points were calculated.




Figure S2. The standard concentration curve of Z_{HPV16 E7} affitoxin384.




Figure S3. The concentrations of Z_{HPV16 E7} affitoxin384 in serum at different time

point post injection.




Figure S4. Detection of $Z_{\text{HPV}16\text{ E7}}$ affitoxin384 antibodies. Serums obtained from five groups of mice in the tumor therapy at day 0 and day 35 were analyzed by ELISA using the recombinant $Z_{\text{HPV}16\text{E7}}$ affitoxin384 as an antigen. * $P < 0.05$, Day 35 versus Day 0.




Table S1. The toxicity of $Z_{\text{HPV}16\text{ E7}}$ affitoxin384

| Dose of $Z_{\text{HPV}16\text{ E7}}$ affitoxin384(nmol/kg) | 500 | 400 | 300 | 200 | 100 | 50 | 20 | 10 | 5 |
|--|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Mortality1 | 5/5 | 1/5 | 0/5 | 1/5 | 0/5 | 0/5 | 0/5 | 0/5 | 0/5 |
| Mortality2 | 5/5 | 2/5 | 0/5 | 0/5 | 0/5 | 0/5 | 0/5 | 0/5 | 0/5 |
| Mortality3 | 5/5 | 4/5 | 2/5 | 1/5 | 0/5 | 0/5 | 0/5 | 0/5 | 0/5 |

Table S2. Complete blood count performed for mice injected with different doses of Z_{HPV16 E7} affitoxin384

| Lists | Doses of Z _{HPV16 E7} affitoxin384 (nmol/kg) | DPI 1 | DPI 3 | DPI 7 | DPI 14 |
|--|---|---------------------|---------------------|----------------------|-----------------------|
| White blood cell count ($\times 10^9$ cells/L) | Control | 1.87 \pm 0.95 | 2.23 \pm 0.78 | 2.17 \pm 0.86 | 1.38 \pm 0.77 |
| | 20 | 1.20 \pm 0.10 | 1.84 \pm 0.68 | 1.97 \pm 0.57 | 0.73 \pm 0.42 |
| | 100 | 1.97 \pm 0.95 | 1.80 \pm 0.30 | 1.63 \pm 1.31 | 1.90 \pm 1.40 |
| | 200 | 1.30 \pm 0.56 | 1.15 \pm 0.15 | 2.00 \pm 0.96 | 1.05 \pm 0.25 |
| Red blood cell count ($\times 10^{12}$ cells/L) | Control | 6.98 \pm 0.04 | 8.41 \pm 0.09 | 8.16 \pm 0.38 | 8.11 \pm 0.34 |
| | 20 | 7.33 \pm 0.02 | 7.92 \pm 0.96 | 7.32 \pm 0.24 | 8.00 \pm 0.45 |
| | 100 | 7.14 \pm 1.04 | 7.91 \pm 0.63 | 7.44 \pm 0.71 | 7.76 \pm 0.59 |
| | 200 | 7.61 \pm 0.63 | 7.12 \pm 0.18 | 7.51 \pm 0.96 | 8.24 \pm 0.50 |
| Platelet count ($\times 10^9$ /L) | Control | 859.67 \pm 157.04 | 895 \pm 149.81 | 1017.33 \pm 52.01 | 933.33 \pm 170.7 |
| | 20 | 616.00 \pm 101.00 | 1038.67 \pm 90.79 | 917.33 \pm 489.04 | 833.67 \pm 535.62 |
| | 100 | 555.67 \pm 240.82 | 1041.5 \pm 41.50 | 1113.33 \pm 619.54 | 1022.67 \pm 125.25 |
| | 200 | 708.00 \pm 84.87 | 976.00 \pm 173.00 | 1361.67 \pm 49.65* | 1448.00 \pm 175.00* |
| Hemoglobin (g/L) | Control | 114.33 \pm 0.60 | 141.00 \pm 4.32 | 138.67 \pm 6.94 | 138.00 \pm 6.98 |
| | 20 | 122.00 \pm 1.00 | 139.67 \pm 17.62 | 130.00 \pm 3.00 | 132.67 \pm 8.33 |
| | 100 | 124.00 \pm 15.59 | 132.50 \pm 10.50 | 124.67 \pm 10.69 | 129.00 \pm 6.24 |
| | 200 | 128.67 \pm 8.74 | 118.50 \pm 3.50 | 128.00 \pm 12.12 | 135.50 \pm 12.50 |
| Hematocrit (%) | Control | 37.33 \pm 0.40 | 44.90 \pm 0.73 | 44.77 \pm 0.76 | 45.07 \pm 0.54 |
| | 20 | 39.55 \pm 0.25 | 50.90 \pm 5.80 | 42.10 \pm 0.17 | 45.57 \pm 3.25 |
| | 100 | 38.67 \pm 6.29 | 49.10 \pm 1.90 | 41.33 \pm 3.67 | 42.43 \pm 2.63 |
| | 200 | 42.47 \pm 1.08 | 44.97 \pm 2.95 | 41.27 \pm 4.05 | 45.30 \pm 3.70 |
| Mean Corpuscular hemoglobin (pg) | Control | 16.40 \pm 0.17 | 16.77 \pm 0.66 | 16.97 \pm 0.61 | 17.03 \pm 0.53 |
| | 20 | 16.65 \pm 0.05 | 17.60 \pm 0.26 | 17.77 \pm 0.49 | 16.57 \pm 0.25 |
| | 100 | 17.40 \pm 0.52 | 16.36 \pm 1.52 | 16.83 \pm 0.25 | 16.63 \pm 0.67 |
| | 200 | 16.93 \pm 0.38 | 16.65 \pm 0.05 | 17.10 \pm 0.70 | 16.35 \pm 0.45 |
| mean corpuscular hemoglobin concentration (g/L) | Control | 306.33 \pm 2.89 | 313.67 \pm 6.60 | 309.33 \pm 12.50 | 306.00 \pm 11.86 |
| | 20 | 309.00 \pm 4.00 | 273.67 \pm 5.03 | 308.67 \pm 6.11 | 291.00 \pm 5.00 |
| | 100 | 322.33 \pm 12.74 | 270.00 \pm 11.00 | 302.33 \pm 9.29 | 303.67 \pm 5.51 |
| | 200 | 303.00 \pm 15.59 | 264.00 \pm 10.00 | 310.33 \pm 4.16 | 299.00 \pm 3.00 |
| mean corpuscular volume (fL) | Control | 53.53 \pm 0.92 | 53.40 \pm 1.40 | 54.93 \pm 2.69 | 55.60 \pm 1.93 |
| | 20 | 54.00 \pm 0.50 | 64.30 \pm 0.44** | 57.60 \pm 2.11 | 56.97 \pm 0.87 |
| | 100 | 54.03 \pm 1.99 | 62.30 \pm 2.50** | 55.63 \pm 1.52 | 54.80 \pm 1.21 |
| | 200 | 55.97 \pm 3.45 | 63.20 \pm 2.60** | 55.13 \pm 2.62 | 54.90 \pm 1.10 |

All experiments were performed in triplicate and data are expressed as means \pm SD (n=3). *P<0.05, **P<0.01 versus the control group.

Table S3. The liver and kidney function panel performed for mice injected with different doses of Z_{HPV16 E7} affitoxin384

| Lists | Doses of Z _{HPV16 E7} affitoxin384 (nmol/kg) | DPI 1 | DPI 3 | DPI 7 | DPI 14 |
|----------------------------------|---|----------------|--------------|-------------|-------------|
| Alanine aminotransferase (U/L) | Control | 50.33±3.77 | 30.00±3.30 | 30.33±8.65 | 49.33±8.06 |
| | 20 | 44.00±4.08 | 36.50±0.50 | 45.33±16.78 | 36.33±8.34 |
| | 100 | 43.67±11.59 | 40.67±4.50 | 37.33±3.30 | 41.67±5.79 |
| | 200 | 41.33±7.85 | 48.67±0.94 | 32.67±6.02 | 36.67±6.24 |
| Aspartate aminotransferase (U/L) | Control | 89.80±13.93 | 49.00±2.05 | 58.33±21.64 | 69.33±12.66 |
| | 20 | 142.00±11.43** | 65.00±4.32 | 64.33±11.01 | 65.00±12.33 |
| | 100 | 135.30±33.77** | 91.33±16.36 | 58.33±6.60 | 57.33±6.18 |
| | 200 | 128.60±15.37** | 113.33±55.86 | 51.33±1.25 | 56.33±7.04 |
| Total protein (g/L) | Control | 57.57±1.27 | 44.73±0.64 | 45.03±2.94 | 46.10±1.85 |
| | 20 | 58.00±4.75 | 48.40±1.69 | 50.63±8.68 | 50.13±3.16 |
| | 100 | 58.87±1.96 | 47.57±2.57 | 46.67±1.29 | 47.27±1.41 |
| | 200 | 53.73±3.90 | 54.37±7.31 | 48.27±0.73 | 51.53±5.57 |
| Albumin (g/L) | Control | 34.37±0.49 | 28.13±0.37 | 28.5±1.07 | 28.73±0.53 |
| | 20 | 34.37±3.02 | 30.13±1.15 | 30.07±3.78 | 30.87±2.10 |
| | 100 | 35.13±1.03 | 28.73±1.44 | 28.50±1.39 | 27.97±3.25 |
| | 200 | 32.20±1.85 | 32.07±4.09 | 29.60±1.23 | 32.10±4.39 |
| Globulin (g/L) | Control | 23.20±1.14 | 16.60±0.33 | 16.53±2.16 | 17.37±1.34 |
| | 20 | 23.63±1.74 | 18.27±0.61 | 20.57±4.97 | 19.27±1.33 |
| | 100 | 23.73±1.35 | 18.83±1.14 | 18.17±0.12 | 19.30±2.12 |
| | 200 | 21.53±2.18 | 22.30±3.30 | 18.67±0.82 | 19.43±1.21 |
| Urea nitrogen (mM) | Control | 10.53±1.45 | 12.03±1.08 | 13.97±1.58 | 11.87±0.38 |
| | 20 | 9.53±0.95 | 7.50±0.64** | 10.83±1.58* | 11.27±0.87 |
| | 100 | 8.37±1.27 | 7.80±0.93** | 10.37±0.82* | 9.33±0.79 |
| | 200 | 9.77±1.70 | 8.97±0.69** | 10.27±0.73* | 12.83±1.27 |
| Creatinine (μM) | Control | 5.33±1.53 | 8.67±0.83 | 11.33±0.47 | 9.67±1.70 |
| | 20 | 6.67±2.51 | 6.67±1.52 | 5.33±3.78 | 7.00±2.64 |
| | 100 | 6.67±2.51 | 7.67±0.58 | 5.33±2.08 | 10.67±1.15 |
| | 200 | 4.67±1.53 | 6.00±1.00 | 7.00±2.64 | 14.00±3.00 |

All experiments were performed in triplicate and data are expressed as means±SD (n=3). *P<0.05,

**P<0.01 versus the control group.